More tools:Markets·Screener·Research·Chat

Novartis AG (NVS) Financial Statements

Novartis AG
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SF5LW6
XNYS · usd
138.00▲ 0.30 (0.22%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close137.70
Day's Range137.12 – 140.46
52-Week Range121.57 – 170.48
Volume10.2M
Avg Volume1.9M
Share Statistics
Shares Outstanding
Employees75.3K
ExchangeXNYS
Listed1996-11-07
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Novartis AG (NVS)
What is Novartis AG's Market Cap?
Novartis AG's Market Cap is $263.3B, based on as-reported figures from SEC (XBRL) filings.
What is Novartis AG's Enterprise Value?
Novartis AG's Enterprise Value is $280.6B, based on as-reported figures from SEC (XBRL) filings.
What is Novartis AG's Trailing P/E?
Novartis AG's Trailing P/E is 18.9×, based on as-reported figures from SEC (XBRL) filings.
What is Novartis AG's Net Income (TTM)?
Novartis AG's Net Income (TTM) is $14.0B, based on as-reported figures from SEC (XBRL) filings.
What is Novartis AG's Diluted EPS (TTM)?
Novartis AG's Diluted EPS (TTM) is 7.32, based on as-reported figures from SEC (XBRL) filings.
What is Novartis AG's Net Debt?
Novartis AG's Net Debt is $17.3B, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Statement [line items]
Net sales from continuing operations
Other revenues
Cost of goods sold
Gross profit from continuing operations
Selling, general and administration
Research and development
Other income
Other expense
Operating income from continuing operations
Loss from associated companies
Interest expense
Other financial income and expense
Income before taxes from continuing operations
Income taxes
Net income from continuing operations
Net income from discontinued operations before gain on distribution—
Net income from discontinued operations—
Net income
Attributable to
Shareholders of Novartis AG
Non-controlling interests